HT
BCRX icon

Headlands Technologies’s BioCryst Pharmaceuticals BCRX Stock Holding History

Headlands Technologies’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$454K Sell
45,351
-27,301
-38% -$247K 0.05% 433
2026
Q1 		$692K Sell
72,652
-45,821
-39% -$356K 0.08% 295
2025
Q4 		$924K Buy
118,473
+4,134
+4% +$29.9K 0.08% 285
2025
Q3 		$868K Buy
114,339
+59,118
+107% +$492K 0.07% 263
2025
Q2 		$495K Buy
55,221
+51,002
+1,209% +$475K 0.06% 303
2025
Q1 		$31.6K Buy
+4,219
New +$34K ﹤0.01% 787
2024
Q3 		– Sell
-16,750
Closed -$104K – 1195
2024
Q2 		$104K Buy
+16,750
New +$92.4K 0.01% 636

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Headlands Technologies's BCRX Position: Q2 2026 in Review

Headlands Technologies reduced its BioCryst Pharmaceuticals (BCRX) stake by 38% in Q2 2026, selling an estimated $247K and leaving 45,351 shares worth $454K. The position accounts for 0.05% of the portfolio, ranked #433.

Headlands Technologies first reported a position in BCRX in Q2 2024 and has held it in 7 quarters since. The position peaked at $924K in Q4 2025. 319 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Headlands Technologies held 45,351 shares of BioCryst Pharmaceuticals worth $454K as of Q2 2026.
  • Headlands Technologies sold 27,301 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $247K.
  • BioCryst Pharmaceuticals made up 0.05% of Headlands Technologies's portfolio in Q2 2026, its #433 holding.
  • Headlands Technologies first reported a position in BioCryst Pharmaceuticals in Q2 2024 and has held it in 7 quarters since.
  • Headlands Technologies's BioCryst Pharmaceuticals position peaked at $924K in Q4 2025.
  • 319 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Headlands Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.